Journal article icon

Journal article

Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells

Abstract:

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are associated with disease-initiating stem cells that are not eliminated by conventional therapies. Transcriptomic analysis of stem and progenitor populations in MDS and AML demonstrated overexpression of STAT3 that was validated in an independent cohort. STAT3 overexpression was predictive of a shorter survival and worse clinical features in a large MDS cohort. High STAT3 expression signature in MDS CD34+ cells was similar to ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1172/jci120156

Authors


More by this author
Role:
Author
ORCID:
0000-0001-5365-6706
Expand authors...
More from this funder
Funding agency for:
Pellagatti, A
More from this funder
Funding agency for:
Boultwood, J
Publisher:
American Society for Clinical Investigation Publisher's website
Journal:
The Journal of Clinical Investigation Journal website
Acceptance date:
2018-09-20
DOI:
EISSN:
1558-8238
ISSN:
0021-9738
Pubs id:
pubs:922539
URN:
uri:e500f944-0e52-42d3-92e1-ab69aba1167b
UUID:
uuid:e500f944-0e52-42d3-92e1-ab69aba1167b
Local pid:
pubs:922539
Language:
English

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP